Nuclear Medicine Communications

Papers
(The H4-Index of Nuclear Medicine Communications is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
The role of fluorodeoxyglucose-PET/computed tomography as a predictor of breast cancer characteristics and prognosis37
Comparison of the role of 18F-fluorodeoxyglucose PET/computed tomography and 68Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma28
[18F]-PSMA-1007 PET imaging optimization and inter-rater reliability – a comparison of three different reconstructions read by four radiologists26
Medical radioisotopes availability: time to look beyond the pandemic25
Is a strict restricted-iodine diet necessary for preparation of radioactive iodine therapy?20
Diagnostic value of single-photon emission computed tomography-CT foot and ankle studies19
Simulated daily readout for maintaining nuclear medicine education in residency training amidst declining case volume: evidence from the COVID-19 pandemic19
In-house development, implementation and evaluation of machine learning software for automated clinical scan processing17
PET/computed tomography radiomics combined with clinical features in predicting sarcopenia and prognosis of diffuse large B-cell lymphoma16
Correlation of 4′-[methyl-11C]-thiothymidine PET with Ki-67 immunohistochemistry separately in patients with newly diagnosed and recurrent gliomas15
Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisation14
Improved 18-FDG PET/CT diagnosis of multiple myeloma diffuse disease by radiomics analysis14
Comparison of 68Ga-FAPI-04 and fluorine-18-fluorodeoxyglucose PET/computed tomography in the detection of ovarian malignancies13
Comparison of reprojected bone SPECT/CT and planar bone scintigraphy for the detection of bone metastases in breast and prostate cancer13
0.18330407142639